ETC
Exchange Traded Concepts Portfolio holdings
AUM
$7.83B
1-Year Return
24.45%
This Quarter Return
-3.99%
1 Year Return
+24.45%
3 Year Return
+83.69%
5 Year Return
+131.49%
10 Year Return
–
AUM
$3.53B
AUM Growth
-$528M
(-13%)
Cap. Flow
-$328M
Cap. Flow
% of AUM
-9.28%
Top 10 Holdings %
Top 10 Hldgs %
29.69%
Holding
1,565
New
259
Increased
499
Reduced
543
Closed
256
Top Buys
| 1 |
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
|
+$366M |
| 2 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$365M |
| 3 |
Emerson Electric
EMR
|
+$26.1M |
| 4 |
Vanguard Energy ETF
VDE
|
+$24.2M |
| 5 |
UnitedHealth
UNH
|
+$16.1M |
Top Sells
| 1 |
Vanguard Long-Term Bond ETF
BLV
|
+$158M |
| 2 |
iShares Core US REIT ETF
USRT
|
+$141M |
| 3 |
Technology Select Sector SPDR Fund
XLK
|
+$138M |
| 4 |
Vanguard Extended Market ETF
VXF
|
+$101M |
| 5 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$69.4M |
Sector Composition
| 1 | Technology | 21.26% |
| 2 | Energy | 11.87% |
| 3 | Healthcare | 10.76% |
| 4 | Industrials | 6.89% |
| 5 | Consumer Discretionary | 5.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
876
ITT
ITT
$13.5B
| $105K | ﹤0.01% |
1,076
+253
| +31% | +$24.8K |
|
877
MacroGenics
MGNX
$111M
| $105K | ﹤0.01% |
22,456
-1,078
| -5% | -$5.02K |
|
878
Summit Therapeutics
SMMT
$14.4B
| $105K | ﹤0.01% |
55,960
-18,073
| -24% | -$33.8K |
|
|
BPMC
879
DELISTED
Blueprint Medicines
BPMC
| $104K | ﹤0.01% |
2,067
-371
| -15% | -$18.6K |
|
880
BlackBerry
BB
$2.29B
| $103K | ﹤0.01% |
+21,864
| New | +$103K |
|
881
Immunocore
IMCR
$1.85B
| $103K | ﹤0.01% |
1,982
-494
| -20% | -$25.6K |
|
|
EQRX
882
DELISTED
EQRx, Inc. Common Stock
EQRX
| $102K | ﹤0.01% |
46,099
-28,713
| -38% | -$63.7K |
|
883
Camden Property Trust
CPT
$11.9B
| $102K | ﹤0.01% |
1,082
+51
| +5% | +$4.82K |
|
884
TD Synnex
SNX
$12.4B
| $102K | ﹤0.01% |
1,021
+38
| +4% | +$3.8K |
|
885
Xencor
XNCR
$600M
| $102K | ﹤0.01% |
5,058
-170
| -3% | -$3.43K |
|
886
Prelude Therapeutics
PRLD
$70.8M
| $102K | ﹤0.01% |
32,907
+7,479
| +29% | +$23.1K |
|
887
Nuvalent
NUVL
$5.76B
| $102K | ﹤0.01% |
2,210
-1,039
| -32% | -$47.8K |
|
|
TSVT
888
DELISTED
2seventy bio
TSVT
| $101K | ﹤0.01% |
25,838
+13,802
| +115% | +$54.1K |
|
889
Merus
MRUS
$5.08B
| $101K | ﹤0.01% |
4,294
-1,125
| -21% | -$26.5K |
|
|
BCYC
890
Bicycle Therapeutics
BCYC
$485M
| $101K | ﹤0.01% |
5,021
-255
| -5% | -$5.12K |
|
891
Fate Therapeutics
FATE
$111M
| $101K | ﹤0.01% |
47,566
+21,955
| +86% | +$46.5K |
|
892
Edison International
EIX
$20.5B
| $101K | ﹤0.01% |
1,592
+445
| +39% | +$28.2K |
|
893
BioNTech
BNTX
$24.7B
| $101K | ﹤0.01% |
926
-304
| -25% | -$33K |
|
894
Geron
GERN
$874M
| $100K | ﹤0.01% |
47,351
+3,749
| +9% | +$7.95K |
|
895
Replimune Group
REPL
$471M
| $100K | ﹤0.01% |
5,849
-49
| -0.8% | -$838 |
|
896
Immuneering
IMRX
$247M
| $99.8K | ﹤0.01% |
12,999
-1,885
| -13% | -$14.5K |
|
897
Aura Biosciences
AURA
$402M
| $99.8K | ﹤0.01% |
11,121
-305
| -3% | -$2.74K |
|
898
Precigen
PGEN
$1.24B
| $99.7K | ﹤0.01% |
70,232
-37,453
| -35% | -$53.2K |
|
899
Apollomics
APLM
$5.99M
| $99.7K | ﹤0.01% |
266
-30
| -10% | -$11.2K |
|
900
Immatics
IMTX
$706M
| $99.4K | ﹤0.01% |
8,585
-3,231
| -27% | -$37.4K |
|